Clinical Significance Of 8q24/c-MYC Translocation In Diffuse Large B ...
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation- Clipboard
- My Bibliography
- Collections
- Citation manager
Save citation to file
Format: Summary (text) PubMed PMID Abstract (text) CSV Create file CancelEmail citation
Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email CancelAdd to Collections
- Create a new collection
- Add to an existing collection
Add to My Bibliography
- My Bibliography
Your saved search
Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons- Yes
- No
Create a file for external citation management software
Create file CancelYour RSS Feed
Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link CopyFull text links
Wiley Free PMC article Full text links Actions
CiteCollectionsAdd to Collections- Create a new collection
- Add to an existing collection
Page navigation
- Title & authors
- Abstract
- Figures
- References
- MeSH terms
- Substances
- LinkOut - more resources
Abstract
Diffuse large B-cell lymphoma (DLBCL) has heterogeneous clinical, histological, and molecular features. We evaluated the clinical characteristics and prognoses of patients with DLBCL carrying 8q24 translocations. A total of 1864 consecutive patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group from 1998 to 2005. Of the 252 patients with DLBCL with abnormal karyotypes, 28 patients with DLBCL with the 8q24 translocation were identified. There were 14 men and 14 women, with a median age of 61 years. The 8q24 translocation was observed significantly more frequently among patients with poor performance status, among patients with high lactate dehydrogenase level, and among patients with bone marrow involvement. The 5-year overall survival was 43.9% among the patients with 8q24 translocation, and 67% among the patients with other chromosomal abnormalities. The 8q24 translocation group showed significantly poorer prognosis than the group with other translocations. In addition, patients with t(14;18) and 8q24 translocation showed significantly poorer prognosis than those with 8q24 translocation alone. It will be necessary to study whether more aggressive chemotherapy or rituximab combination chemotherapy is effective in 8q24 translocation cases.
PubMed Disclaimer
Figures
Figure 1
(a) Overall and (b) progression‐free…
Figure 1
(a) Overall and (b) progression‐free survival curves of patients with diffuse large B‐cell…
Figure 2
(a) Overall and (b) progression‐free…
Figure 2
(a) Overall and (b) progression‐free survival curves of patients with diffuse large B‐cell…
Figure 3
(a) Overall and (b) progression‐free…
Figure 3
(a) Overall and (b) progression‐free survival curves of patients with diffuse large B‐cell…
References
-
- Shipp MA. International non‐Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–94. - PubMed
-
- Vega F, Medeiros LJ. Chromosomal translocations involved in non‐Hodgkin lymphomas. Arch Pathol Lab Med 2003; 127: 1148–60. - PubMed
-
- Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma 2004; 45: 519–28. - PubMed
-
- Niitsu N, Okamoto M, Aoki S, Kuraishi Y, Okumura H, Hirano M. Multicenter phase II study of the CyclOBEAP (CHOP‐like + etoposide and bleomycin) regimen for patients with poor‐prognosis aggressive lymphoma. Ann Haematol 2006; 85: 374–80. - PubMed
-
- Sánchez‐Beato M, Sánchez‐Aguilera A, Piris MA. Cell cycle deregulation in B‐cell lymphomas. Blood 2003; 101: 1220–35. - PubMed
MeSH terms
- Adult Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Aged Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Aged, 80 and over Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Chromosome Aberrations Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Chromosomes, Human, Pair 8 / genetics* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Female Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Humans Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Lymphoma, Large B-Cell, Diffuse / genetics* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Lymphoma, Large B-Cell, Diffuse / pathology Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Male Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Middle Aged Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Prognosis Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Proto-Oncogene Proteins c-myc / genetics* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Survival Rate Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Translocation, Genetic / genetics* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
Substances
- MYC protein, human Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Proto-Oncogene Proteins c-myc Actions
- Search in PubMed
- Search in MeSH
- Add to Search
LinkOut - more resources
Full Text Sources
- Europe PubMed Central
- Ovid Technologies, Inc.
- PubMed Central
- Wiley
Research Materials
- NCI CPTC Antibody Characterization Program
Wiley Free PMC article [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To - Clipboard
- Save
- My Bibliography
- Collections
- Citation Manager
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Từ khóa » C Myc 8q24
-
Isabella C. Glitza - NCBI
-
Long-range Enhancers On 8q24 Regulate C-Myc - PNAS
-
The Clinical Significance Of 8q24/MYC Rearrangement In Chronic ...
-
The Role Of 8q24 Copy Number Gains And C-MYC Expression ... - Nature
-
C-MYC _ 8q24 | FISH - Washington University Pathology Services
-
MYC (8q24) - NeoGenomics Laboratories
-
MYC (8q24) Break Apart FISH Probe Orange/Green - Biocare Medical
-
C-MYC(8q24) Gene Amplification ... - Celnovte Biotechnology
-
C MYC 8q24 Rearrangement By FISH | Test Menu
-
C-MYC(8q24) Gene Amplification ... - Celnovte Biotechnology
-
MYC (8q24) Gene Rearrangement By FISH - ARUP Lab Test Directory
-
High-grade B-cell Lymphoma/leukemia Associated With T(14;18) And ...
-
[PDF] MYC-positive Lymphomas Other Than Burkitt's Lymphoma - EHA Library
-
The Role Of C-MYC In B-Cell Lymphomas: Diagnostic And Molecular ...